The USPTO issued patent US12589159B2 to ARO Biotherapeutics Company for CD71 binding fibronectin type III domain compositions and methods. The patent covers FN3 polypeptides that bind CD71 (transferrin receptor), along with conjugates, encoding nucleotides, vectors, host cells, and methods of making and using these molecules. The 18 granted claims protect compositions comprising these FN3 domains and their therapeutic applications.

This is a routine patent grant notice with no immediate compliance obligations. For companies developing FN3-based CD71-targeted therapeutics, this patent may represent a freedom-to-operate consideration. ARO Biotherapeutics now holds enforceable IP rights in this space, which could affect licensing discussions or competitive development timelines.